ELDOPER Capsule

គុណភាពព្យាបាល: 
- ឡូប៉េរ៉ាម៉ីដ ជាឱសថប្រឆាំងនឹងជម្ងឺរាក
- ឡូប៉េរ៉ាម៉ីដ មានសកម្មភាពបន្ថយចលនាពោះវៀន ដោយធ្វើអោយជ្រាបទឹក និង electrolyte ចេញមកក្រៅពោះវៀន
- ឱសថនេះសំរាប់ព្យាបាលជម្ងឺរាកធ្ងន់ធ្ងរ និងរ៉ាំរ៉ៃ និងរលាកពោះវៀន
- ឱសថនេះប្រើសំរាប់បន្ថយលាមកតាមផ្លូវធម្មតាដោយបញ្ចេញលាមកតាមផ្លូវសិប្បនិម្មិត្ត។
<strong>កំរិតនិងរបៀបប្រើ: </strong>
- ជម្ងឺរាកធ្ងន់ធ្ងរ :
+ ចំពោះមនុស្សពេញវ័យ: កំរិតប្រើធម្មតាពី 3 ទៅ 4 គ្រាប់ ក្នុង1ថ្ងៃ ប្រើកំរិតដំបូង2គ្រាប់។ បើមានរាកទៀត ថែមម្ដង1គ្រាប់ បើនៅរាកបន្តថែមរហូតដល់កំរិតអតិបរមា 8គ្រាប់ ក្នុង24ម៉ោង
+ ចំពោះក្មេង : មិនត្រូវប្រើចំពោះក្មេងអាយុក្រោម2ឆ្នាំ
・ប្រើសំរាប់អាយុពី6 ទៅ8ឆ្នាំ (20-30គ.ក្រ) ព្រឹក1គ្រាប់ ល្ងាច1គ្រាប់ (2គ្រាប់ក្នុង1ថ្ងៃ)
・ប្រើសំរាប់អាយុពី8 ទៅ12ឆ្នាំ (>30គ.ក្រ) ព្រឹក1គ្រាប់ ថ្ងៃ1គ្រាប់ ល្ងាច1គ្រាប់ (3គ្រាប់ក្នុង1ថ្ងៃ)
・ជម្ងឺរាករ៉ាំរ៉ៃចំពោះមនុស្សពេញវ័យ : កំរិតប្រើដំបូង 2 ទៅ 4 គ្រាប់ក្នុង1ថ្ងៃ
・មិនត្រូវប្រើអោយលើសពី 8គ្រាប់ក្នុង1ថ្ងៃ (លេប 2ឬ3ដង ក្នុង1ថ្ងៃ)។

For the control and symptomatic relief of acute nonspecific diarrhoea and chronic diarrhoea associated with inflammatory bowel disease. Loperamide is also indicated for reducing the volume of discharge from ileostomies.

Dosage and administration

Acute diarrhoea:

Adults: The recommended initial dose is 4mg followed by 2mg after each unformed stool upto maximum of 16mg daily. Usual daily dose is 6-8mg.

Children: Loperamide use is not recommended for children under 2 years of age. The recommended dose for other age groups are:

6-8 years (20-30kg): 2mg bid (4mg/day)

8-12 years (>30kg): 2mg tid (6mg/day)

Chronic diarrhoea:

Adults: The usual initial dose is 4-8mg daily in divided doses subsequently adjusted as necessary. Doses of 16mg daily should not be exceeded. If no improvement is observed after treatment with 16mg daily for at least 10days further administration is unlikely to be of benefit.

The use of Loperamide does not preclude the administration of appropriate fluid and electrolyte replacement therapy.

ហាមប្រើ: 
- អ្នកជម្ងឺធ្លាប់មានប្រតិកម្មជាមួយឱសថនេះ និងអ្នកទល់លាមក។

In patients with known hypersensitivity to the drug and in those in whom constipation must be avoided.

ផលរំខានខ្លះៗ: 
ឈឺពោះ ក្អួតចង្អោរ ទល់លាមក ស្ងួតមាត់ វិលមុខ ហត់ និង ប្រតិកម្មកន្ទួលលើស្បែក

Abdominal pain, nausea, constipation, dry mouth, dizziness, fatigue, and hypersensitivity reactions including skin rashes have been reported. Loperamide hydrochloride has been associated with paralytic ileus, particularly in infants and young children, and deaths have been reported. Depression of the CNS, to which children may be more sensitive, may be seen in overdosage and Naloxone hydrochloride has been recommended for its treatment.

There was no evidence in clinical trials of drug interactions with concurrent medications.

ប្រុងប្រយ័ត្នចំពោះស្ត្រីមានផ្ទៃពោះ ជាពិសេសកំឡុងត្រីមាសទី1 និងស្ត្រីបំបៅកូន។

Although there are no indications that Loperamide possesses teratogenic or embryotoxic properties, the anticipated therapeutic benefits should be weighed against potential hazards before Loperamide is given during pregnancy, especially during the first trimester.

There is little information on the excretion of Loperamide in human milk, but as small amounts of the drug were detectable in the mild of a nursing mother, the use of Loperamide is not recommended in breastfeeding subjects.

ការប្រុងប្រយ័ត្ន: 
- ចំពោះអ្នកជម្ងឺខ្សោយថ្លើម
- ចំពោះការប្រើឱសថនេះលើកុមារ
- ថ្នាំនេះមិនគួរប្រើលើអ្នកជម្ងឺរាកមួល
- ករណីប្រើឡូប៉េរ៉ាមីដលើសកំរិតត្រូវប្រើ Loxone ដើម្បីបន្សាប
- ចំពោះស្ត្រីមានផ្ទៃពោះ ជាពិសេសកំឡុងត្រីមាសទី1 និងស្ត្រីបំបៅកូន
 

Loperamide should be used with caution in patients with hepatic dysfunction because of its considerable first-pass metabolism in the liver. It should also be used with caution in young children because of a greater variability of response in this age group and it is not generally recommended for use in infants. Patients with inflammatory bowel diseases or pseudomembranous colitis receiving Loperamide should be carefully observed for signs of toxic megacolon. Loperamide should not be used in patients with dysentery.

Loperamide acts by slowing intestinal motility and by affecting water and electrolyte movement through the bowel. Loperamide inhibits peristaltic activity by a direct effect on the circular and longitudinal muscles of the intestinal wall. Loperamide prolongs the transit time of the intestinal contents and reduces the daily fecal volume, increases the viscosity and bulk density, and diminishes the loss of fluid and electrolytes. Tolerance to the antidiarrheal effect has not been observed.